You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News and reporting on ALK biomarkers.
A Pfizer research group, working with Seoul's Samsung Medical Center, has published a study demonstrating a multiplex method for detecting ALK, ROS1, and RET fusions in a single assay.
Originally published Oct. 29.
Originally published May 7.
In the first quarter of this year, pharmacogenetically targeted cancer drugs Xalkori and Zelboraf had marked increases in revenues from the previous year's quarter.
Originally published April 8.
Originally published April 9.
Boehringer Ingelheim has launched a campaign to educate healthcare providers about biomarker testing to personalize treatment for non-small cell lung cancer patients.
Insight Genetics has been awarded a contract from the National Cancer Institute worth nearly $1.5 million to begin clinical testing of its qPCR-based assay for ALK mutations in lung cancer.
This article has been updated to correct the name of the Phase I extension trial to Study 1001. Originally published June 3.
By Turna Ray
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.